Design and synthesis of potent and selective macrocyclic thrombin inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 16, 2003, Pages 2781-2784

  Nantermet, Philippe G ^a   Barrow, James C ^a   Newton, Christina L ^a   Pellicore, Janetta M ^a   Young, MaryBeth ^a   Lewis, S Dale ^a   Lucas, Bobby J ^a   Krueger, Julie A ^a   McMasters, Daniel R ^a   Yan, Youwei ^a   Kuo, Lawrence C ^a   Vacca, Joseph P ^a   Selnick, Harold G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROLINE DERIVATIVE; PYRAZINOIC ACID DERIVATIVE; THROMBIN; THROMBIN INHIBITOR; TRYPSIN; TRYPSIN INHIBITOR;

ARTICLE; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; MOLECULAR DYNAMICS; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

EID: 12444322672     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00506-7     Document Type: Article

References (23)

1. Thrombosis in Cardiovascular Disorders; Fuster, V., Verstraete, M., Eds.; W.B. Saunders: Philadelphia, 1992.
2. Parenteral administration of low molecular weight heparin and intense patient monitoring required with warfarin limit their chronic utility.
3. Adang A.E.P., Rewinkel J.B.M. Drugs Future. 25:2000;369.
4. Coburn C.A. Exp. Opin. Ther. Patents. 11:2001;1 Sanderson P.E.J. Annu. Rep. Med. Chem. 36:2001;79 Vacca J.P. Annu. Rep. Med. Chem. 33:1998;81.
5. Coburn C.A. Exp. Opin. Ther. Patents. 11:2001;1 Sanderson P.E.J. Annu. Rep. Med. Chem. 36:2001;79 Vacca J.P. Annu. Rep. Med. Chem. 33:1998;81.
6. Coburn C.A. Exp. Opin. Ther. Patents. 11:2001;1 Sanderson P.E.J. Annu. Rep. Med. Chem. 36:2001;79 Vacca J.P. Annu. Rep. Med. Chem. 33:1998;81.
7. (a) Tucker T.J., Brady S.F., Lumma W.C., Lewis S.D., Gardell S.J., Naylor-Olsen A.M., Yan Y., Sisko J.T., Stauffer K.J., Lucas B.J., Lynch J.J., Cook J.J., Stranieri M.T., Holahan M., Lyle E.A., Baskin E.P., Chen I.W., Dancheck K.B., Krueger J.A., Cooper C.M., Vacca J.P. J. Med. Chem. 41:1998;3210
8. (b) Tucker T.J., Lumma W.C., Mulichak A.M., Chen Z., Naylor-Olsen A.M., Lewis S.D., Lucas B.J., Freidinger R.M., Kuo L.C. J. Med. Chem. 40:1997;830.
9. Burgey C.S., Robinson K.A., Lyle T.A., Sanderson P.E.J., Lewis S.D., Lucas B.J., Krueger J.A., Lyle E.A., Stranieri M.T., Holahan M., Sitko G.R., Cook J.J., Wallace A.A., Clayton F., Bohn D., Leonard Y., Detwiler T., Lynch J.J., Williams P.D., Coburn C.A., Dorsey B.D., McMasters D.R., McDonough C.M., Sanders W.M., Gardell S.J., Shafer J.A., Vacca J.P. J. Med. Chem. 46:2003;461.
10. 4.
11. (a) Tyndall J.D.A., Fairlie D.P. Curr. Med. Chem. 8:2001;893
12. (b) Greco M.N., Maryanoff B.E. Adv. Amino Acid Mimet. Peptidomimet. 1:1997;41
13. (c) Greco M.N., Powell E.T., Hecker L.R., Andrade-Gordon P., Kauffman J.A., Lewis J.M., Ganesh V., Tulinsky A., Maryanoff B.E. Bioorg. Med. Chem. Lett. 6:1996;2947
14. (d) Maryanoff B.E., Zhang H.C., Greco M.N., Glover K.A., Kauffman J.A., Andrade-Gordon P. Bioorg. Med. Chem. 3:1995;1025.
15. Horwell D.C., Hugues J., Hunter J.C., Pritchard M.C., Richardson R.S., Roberts E., Woodruff G.N. J. Med. Chem. 34:1991;404.
16. Nantermet P.G., Selnick H.G. Tetrahedron Lett. 44:2003;2401.
17. Furstner A., Langemann K. Synthesis. 1997;792.
18. Lewis S.D., Ng A.S., Lyle E.A., Mellott M.J., Appelby S.D., Brady S.F., Stauffer K.S., Sisko J.T., Mao S.-S., Veber D.F., Nutt R.F., Lynch J.J., Cook J.J., Gardell S.J., Shafer J.A. Thromb. Haemost. 74:1995;1107.
19. Tucker T.J., Lumma W.C., Lewis S.D., Gardell S.J., Lucas B.J., Baskin E.P., Woltmann R., Lynch J.J., Lyle E.A., Appleby S.D., Chen I.-W., Dancheck K.B., Vacca J.P. J. Med. Chem. 40:1997;1565.
20. Calculated LogP (ChemDraw) for 20 and 23 are 3.7 and 2.6. respectively.
21. Lumma W.C., Witherup K.M., Tucker T.J., Brady S.F., Sisko J.T., Naylor-Olsen A.M., Lewis S.D., Lucas B.J., Vacca J.P. J. Med. Chem. 41:1998;1011.
22. (a) Multiple conformations of the macrocycles were generated using the metric matrix distance geometry algorithm JG (S. Kearsley, Merck & Co., Inc., unpublished). The generated conformers were energy-minimized within the thrombin active site using MacroModel (ref 17b) with the MMFF force field, and allowing Glu192 to adjust to the inhibitor. (b) Mohamadi F., Richards N.G.J., Guida W.C., Liskamp R., Lipton M., Caufield C., Chang G., Hendrickson T., Still W.C. J. Comput. Chem. 11:1990;440.
23. Differences in electrostatic potential caused by E/Q192 have been proposed as an important factor in the selective binding of PAI-1 to tPA versus thrombin. Rezaie A.R. Biochemistry. 37:1998;13138.